Gilles Bernard Tremblay
Director Técnico/Científico/I+D en Alethia Biotherapeutics, Inc. .
Perfil
Gilles Bernard Tremblay is currently the Vice President-Research at Alethia Biotherapeutics, Inc. He started this position in 2012.
Previously, he worked as a Group Leader at SignalGene, Inc. Dr. Tremblay holds a doctorate degree from McGill University.
Cargos activos de Gilles Bernard Tremblay
| Empresas | Cargo | Inicio |
|---|---|---|
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Director Técnico/Científico/I+D | 01/01/2000 |
Antiguos cargos conocidos de Gilles Bernard Tremblay.
| Empresas | Cargo | Fin |
|---|---|---|
| SignalGene, Inc. | Corporate Officer/Principal | - |
Formación de Gilles Bernard Tremblay.
| McGill University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Health Technology |
| SignalGene, Inc. |
- Bolsa de valores
- Insiders
- Gilles Bernard Tremblay
